Mar 6, 2024 7:30 am EST Rezolute Reports Validation of the Potential Use of RZ358 for Treatment of Non-Islet Cell Tumor Hypoglycemia (NICTH)
Feb 13, 2024 4:05 pm EST Rezolute Reports Second Quarter Fiscal 2024 Results and Provides Business Update
Jan 24, 2024 8:00 am EST Rezolute Expands Leadership Team with Appointment of Daron Evans, MS, MBA, as Chief Financial Officer
Jan 23, 2024 8:00 am EST Rezolute Receives Innovation Passport Designation from the U.K. Innovative Licensing and Access Pathway Steering Group for RZ358 in the Treatment of Hypoglycemia Due to Congenital Hyperinsulinism
Dec 14, 2023 8:00 am EST Rezolute Initiates Phase 3 Clinical Study for RZ358 in Congenital Hyperinsulinism
Dec 13, 2023 8:00 am EST Rezolute Completes Enrollment of its Phase 2 Study in Diabetic Macular Edema (“DME”)
Oct 17, 2023 8:00 am EDT Rezolute Receives Priority Medicines (PRIME) Eligibility from European Medicines Agency for Enhanced Regulatory Support of RZ358 in Congenital Hyperinsulinism
Oct 11, 2023 8:00 am EDT Rezolute Announces Further Evidence of RZ358’s Efficacy in Tumor-Mediated Hyperinsulinism
